Furthermore, these data suggest that HLA-DR expression in melanoma cells may be a biomarker for tumours primed with activated T-cells and an appropriate IFNγ response to mediate sensitivity to PD-1/PD-L1 blockade. The gene discussed is IFNG; the disease is neoplasm.